Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Frontotemporal Dementia AND Alzheimer Disease

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Frontotemporal Dementia AND Alzheimer Disease. Displaying page 1 of 1.
    EudraCT Number: 2014-002013-37 Sponsor Protocol Number: TRx-237-020 Start Date*: 2014-10-06
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: An Open-Label, Extension Study of the Effects of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Alzheimer’s Disease or Behavioral Variant Frontotemporal Dementia
    Medical condition: Alzheimer’s Disease and behavioral variant Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    19.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) FI (Prematurely Ended) BE (Completed) HR (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023852-10 Sponsor Protocol Number: 18F-AV-45-020 Start Date*: 2011-10-03
    Sponsor Name:Avid Radiopharmaceuticals, Inc.
    Full Title: 18F-AV-45 Amyloid PET Imaging in Primary Progressive Aphasia
    Medical condition: Focal dementia syndromes - primary aphasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012292 Dementia of the Alzheimer's type NOS LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001315-40 Sponsor Protocol Number: RF-2010-2319722 Start Date*: 2014-12-03
    Sponsor Name:IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
    Full Title: Amyloid Imaging in the “Italian Network for autosomal dominant Alzheimer’s disease and frontotemporal lobar degeneration (ItalianDIAfN)”
    Medical condition: Autosomal Dominant Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005529-34 Sponsor Protocol Number: TRx-237-007 Start Date*: 2012-12-28
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Behavioral Variant Frontotem...
    Medical condition: behavioral variant Frontotemporal Dementia (bvFTD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) NL (Completed) IT (Completed) FI (Completed) PL (Completed) ES (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2017-000094-36 Sponsor Protocol Number: BioFINDER_2 Start Date*: 2017-03-31
    Sponsor Name:Skåne University Hospital
    Full Title: The BioFINDER 2 study - improved diagnostics and increased understanding of the pathophysiology of cognitive disorders
    Medical condition: Neurodegenerative disorders with Tau-pathology; including, but not limited to, Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and mild cogni...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    19.1 10029205 - Nervous system disorders 10012267 Dementia PT
    19.1 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    19.1 10029205 - Nervous system disorders 10028037 Movement disorders (incl parkinsonism) HLGT
    19.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    19.1 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    19.1 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    19.1 10029205 - Nervous system disorders 10048598 Cognitive disorders LLT
    19.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    19.1 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    19.1 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    19.1 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    19.1 10029205 - Nervous system disorders 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-002267-29 Sponsor Protocol Number: WVE-004-002 Start Date*: 2022-10-14
    Sponsor Name:Wave Life Sciences UK Limited
    Full Title: A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinical Effects of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and...
    Medical condition: Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) IE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-005733-16 Sponsor Protocol Number: DNLI-H-0001 Start Date*: 2022-07-19
    Sponsor Name:Denali Therapeutics Inc.
    Full Title: A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in ...
    Medical condition: Frontotemporal Dementia (FTD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) PT (Trial now transitioned) CZ (Completed) FR (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-003159-12 Sponsor Protocol Number: J4B-MC-OKAA Start Date*: 2021-12-24
    Sponsor Name:Prevail Therapeutics, a wholly-owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN) (PROCLAIM)
    Medical condition: Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Temporarily Halted) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-004066-18 Sponsor Protocol Number: AL001-3 Start Date*: 2020-07-06
    Sponsor Name:Alector Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk For or With Frontotemporal Dementia Due to Heterozygou...
    Medical condition: Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PT (Trial now transitioned) NL (Trial now transitioned) ES (Temporarily Halted) BE (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000422-38 Sponsor Protocol Number: PET_imaging_of_Tau Start Date*: 2014-09-19
    Sponsor Name:Skåne University Hospital, Region Skåne
    Full Title: An open-label study evaluating the diagnostic accuracy of [18F]-AV-1451 PET to detect and distinguish neurodegenerative disorders characterized by cerebral accumulation of tau
    Medical condition: Neurodegenerative disorders with Tau-pathology; including Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, corticobasal degeneration and important differential diagnost...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    17.0 10029205 - Nervous system disorders 10053643 Neurodegenerative disorder PT
    17.0 10029205 - Nervous system disorders 10009846 Cognitive impairment LLT
    17.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    17.0 10029205 - Nervous system disorders 10012285 Dementia due to Pick's disease LLT
    17.0 10029205 - Nervous system disorders 10012267 Dementia PT
    17.0 10029205 - Nervous system disorders 10067889 Dementia with Lewy bodies PT
    17.0 10029205 - Nervous system disorders 10036813 Progressive supranuclear palsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002251-11 Sponsor Protocol Number: TPN-101-C9-201 Start Date*: 2021-12-06
    Sponsor Name:Transposon Therapeutics, Inc
    Full Title: A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia)
    Medical condition: Amyotrophic lateral sclerosis or frontotemporal dementia due to a genetic mutation called C9orf72 hexanucleotide repeat expansion
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000138-20 Sponsor Protocol Number: AL001-2 Start Date*: 2019-11-18
    Sponsor Name:Alector Inc.
    Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of...
    Medical condition: Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10068968 Frontotemporal dementia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002568-62 Sponsor Protocol Number: AVB-PGRN-001 Start Date*: 2023-03-13
    Sponsor Name:AviadoBio Ltd
    Full Title: A Phase 1/2 Open-Label, Ascending Dose, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal...
    Medical condition: Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005915-13 Sponsor Protocol Number: TRx-014-002 Start Date*: 2006-07-12
    Sponsor Name:TauRx Therapeutics PTE Ltd
    Full Title: An Open Pilot Study of Methlythioninium Chloride (MTC) in Frontotemporal Dementia and Related Dementia Syndromes
    Medical condition: Frontotemporal Dementia and related syndromes Prevention and reversal of tau protein aggregation is a novel approach to the treatment of patients with FTD and related syndromes and has the potent...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10012267 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003597-18 Sponsor Protocol Number: 18F-AV-45-010 Start Date*: 2009-05-28
    Sponsor Name:Avid Radiopharmaceuticals, Inc
    Full Title: A study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer's disease and normal controls
    Medical condition: Use of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10061816 Diagnostic procedure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002997-30 Sponsor Protocol Number: RA-201902-2017958 Start Date*: 2021-01-25
    Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA
    Full Title: Dopaminergic Therapy for Frontotemporal Dementia Patients
    Medical condition: Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002227-13 Sponsor Protocol Number: ACP-103-045 Start Date*: 2018-02-04
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis
    Medical condition: Hallucinations and Delusions Associated With Dementia-related Psychosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012295 Dementia of the Alzheimer's type, with delusions PT
    20.0 100000004873 10019077 Hallucinations LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) SK (Prematurely Ended) BG (Completed) ES (Prematurely Ended) PL (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003536-36 Sponsor Protocol Number: ACP-103-046 Start Date*: 2018-09-03
    Sponsor Name:ACADIA Pharmaceuticals Inc.
    Full Title: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects With Neuropsychiatric Symptoms Related to Neurodegenerativ...
    Medical condition: Neuropsychiatric Symptoms Related to Neurodegenerative Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-004328-40 Sponsor Protocol Number: INMINDFP7-HEALTH-2011-two-stage Start Date*: 2013-03-01
    Sponsor Name:OSPEDALE S. RAFFAELE DI MILANO
    Full Title: IMAGING OF NEUROINFLAMMATION IN NEURODEGENERATIVE DISEASES
    Medical condition: mild cognitive impairment, Alzheimer disease,frontotemporal dementia, SLA
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10050727 RI scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:32:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA